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The introduction of  endoscopy into Malawi both enables the 
re-evaluation of  medical practice and opens many possibilities 
for research and future development of  medical care. There 
are currently endoscopy units at Blantyre, Lilongwe and 
Zomba, and we hope and expect that in the future more 
units will be opened. Endoscopy units offer both upper and 
lower gastrointestinal (GI) examinations, although at present 
the vast majority of  procedures performed in Malawi are 
studies of  the upper GI tract.
What is upper gastrointestinal endoscopy?
Oesopho-gastro-duodenoscopy (OGD) involves the 
introduction of  an endoscope, effectively a long flexible 
tube, through the pharynx into the oesophagus. The tube is 
controllable in two planes by the use of  wheels; the operator 
has further control by use of  rotation or “torque” of  the 
endoscope. Traditionally endoscopes were fibreoptic, with 
fibres running the length of  the tube transmitting the image 
to a camera attached next to the controls.  Newer endoscopes 
have a video chip similar to that in many mobile phones, 
making the endoscope more robust. A light source illuminates 
the field of  view, and two separate channels run the length 
of  the tube: the first to enable washing of  the mucosa and 
the lens at the front, the second for both for suction and 
the passage of  instruments, such as snares, biopsy forceps 
and needles for injection. Thus the endoscope both provides 
macroscopic diagnostic information and can sample tissue 
for histopathological or microbiological analysis. In addition 
therapeutic techniques can be performed: ulcers can be 
injected through the biopsy channel, polyps removed, and 
varices injected or ligated with small rubber bands. In skilled 
hands it is possible to perform mucosal and sub mucosal 
dissection of  large lesions, and separate tools are available 
for dilatation of  strictures and the insertion of  stents.
Indications for upper GI endoscopy
The major indication for OGD in Malawi, and indeed 
elsewhere, is for epigastric pain1,2. Here it is most commonly 
referred to as PUD or Peptic Ulcer Disease, though this is 
in fact a misnomer, as the vast majority of  patients who are 
suspected to have PUD do not have an ulcer. Most commonly 
in these patients, OGD reveals evidence of  gastritis.  But a 
wide variety of  other conditions may cause epigastric pain. 
In some of  these the pain originates from the  GI tract – 
for example gastro-oesophageal reflux disease(GORD)and 
functional dyspepsia3 – and in others the source of  pain is 
outside the gastrointestinal tract – eg biliary colic and chronic 
pancreatitis. The symptoms may vary only slightly between 
these different conditions, and very careful history-taking is 
crucial to try and differentiate between them.
Gastritis
In many patients OGD reveals gastritis, or inflammation of  
the lining of  the stomach. It has a number of  causes: drugs, 
infection (particularly H pylori) and other rarer conditions 
such as autoimmune disease. Medications known to cause 
gastritis include aspirin and the other drugs from the class of  
non steroidal anti-inflammatory drugs (NSAIDS)4, such as 
ibuprofen (Brufen), indomethacin (Indocid) and diclofenac. 
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These drugs can also cause ulceration of  the gastric and 
duodenal mucosa. Patients with epigastric pain should 
therefore not be prescribed ibuprofen (currently a popular 
drug among prescribers), as it is likely to exacerbate their 
symptoms. One of  the first interventions in any patient with 
epigastric pain is to stop any NSAIDs they may be taking.
Helicobacter pylori
H pylori is a spiral shaped Gram positive urease-producing 
bacterium. It lives under the layers of  mucus in the gastric 
pits. It is found mostly in the gastric antrum, but can be 
elsewhere in both the stomach and duodenum. In patients 
who have been taking Proton Pump Inhibitors it migrates to 
the fundus5. H pylori is associated with lower socioeconomic 
status6 and is thought to be acquired early in childhood, most 
probably from other family members7. The rates of  H pylori 
carriage are thought to be high in Malawi8. In the longer 
term H pylori is associated with both peptic ulcer disease9 
and gastric cancer10. In sub Saharan Africa, despite the 
known high rate of  carriage of  H pylori the rate of  gastric 
cancers seems to be relatively low, a phenomenon which is 
unexplained11. In addition some individuals with chronic H 
pylori infection develop atrophy of  the gastric mucosa and 
achlorhydria12. This may reduce the natural anti-bacterial 
effect of  the stomach fluid and increase the risk of  a variety 
of  GI infections occurring. HIV is known to have a similar 
effect of  raising gastric pH13 and it could be postulated that 
the HIV and H pylori may have a synergistic effect resulting in 
an increase in the susceptibility of  an individual to infections 
such as Salmonella sp. The vast majority of  patients with 
H pylori are asymptomatic carriers. Despite this, since it is 
known to be associated with dyspepsia, it seems sensible to 
give presumptive treatment in an attempt to eradicaten of  H 
pylori in  patients who present with suggestive symptoms, 
and only to resort to endoscopy in those whose symptoms 
persist. The exception to this is in patients with so called “red 
flag” symptoms, in whom OGD is indicated immediately. 
These symptoms are weight loss, dysphagia (difficulty 
swallowing), persistent vomiting, haematemesis or melena, 
and an epigastric mass; in these patients, as well as those aged 
over 55 with persistent symptoms, a referral for endoscopy 
is indicated14.
Drug treatment for suspected H pylori infection 
Treatment for H pylori involves a combination of  acid-
suppression and antibiotics. This has classically been “triple 
therapy” a combination of  a proton pump inhibitor (PPI) and 
two separate antibiotics. Currently in Malawi the recommended 
PPI is omeprazole and the antibiotics are amoxicillin 1g bd 
and metronidazole 500mg bd.  Metronidazole resistance in 
H. pylori in Malawi was described as being as high as 85% 
in Lilongwe8 and therefore patients are given two weeks of  
therapy rather than the standard seven days suggested by the 
British National Formulary. It is suspected, though currently 
not known, that there is a high rate of  treatment failure among 
our patients on this therapy regimen. There are a number of  
alternatives. Exposure to metronidazole may be high in some 
sections of  our population, and an alternative triple therapy 
regime  that is soetimes effective is omeprazole, amoxicillin 
and clarithromycin. Higher rates of  successful eradication 
have been described using a “quadruple therapy”, which 
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consists of  adding bismuth chelate to the current regime. 
There have been reports of  sequential dosing regimes but 
most of  these make use of  more expensive antibiotics not 
available in Malawi15.
‘Functional’ dyspepsia
Although there is an association between H pylori and 
epigastric pain, eradication does not necessarily result in an 
improvement in pain. A number of  patients who have had 
successful eradication still have ongoing symptoms16. This 
group is often described as having functional dyspepsia, or 
non-ulcer dyspepsia. As with all functional bowel disease, the 
symptoms are common and result in frequent consultations 
to medical services. This condition is not associated with 
any increase in mortality. The prevalence and incidence of  
this condition in Malawi are unknown, but experience in the 
clinic and endoscopy unit suggest that it is common.  
Other causes of dyspeptic symptoms
It would be interesting to investigate what other causes 
of  epigastric pain occur commonly in Malawi and should 
be more routinely considered in the differential diagnosis. 
Abdominal tuberculosis can present with abdominal pain17: 
no one knows the incidence of  this disease in our population, 
although with the increase in extra pulmonary tuberculosis 
in HIV-infected people  it might be expected to be rising. 
Similarly in schistosomiasis due to S mansoni, which is 
common here, the presence of  adult worms in mesenteric 
veins or the passage of  ova through the wall of  the gut might 
be associated with epigastric discomfort. 
Conclusion
The development of  endoscopy services in Malawi offers 
the chance of  improving patient care and raises a number 
of  questions about the way we treat common symptoms. 
Endoscopy has shown that what clinicians suspect to be 
Peptic Ulcer Disease rarely is. It will hopefully become clearer 
in the future what associations there are between H pylori 
and other diseases, and what are the best treatment options. 
Meanwhile endoscopy plays an important role in excluding 
peptic ulcer disease in many patients and identifying it in a 
few, and in making a range of  other diagnoses. 
Addendum
Endoscopy has an increasing role in the treatment of  other 
conditions such as oesophageal varices, which will be the 
subject of  another article in this series.
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